This Hot Growth Stock Is Still a Buy After Enormous Gains
Vaccine giant Moderna (NASDAQ: MRNA) has gained a jaw-dropping 1,200% over the past two years. That's after the biotech company developed a coronavirus vaccine and brought it to market in about nine months. And after Moderna followed up by generating billions of dollars in revenue and profit from the vaccine.
So, there have been plenty of reasons to like this hot growth stock since the beginning of the coronavirus pandemic. In recent months, though, some investors have started to take a step back from Moderna. The big concern is vaccine revenue will eventually decline -- and this is Moderna's only commercialized product. But I'm not overly worried. I think this biotech stock still is a buy after its enormous gains, and here's why.
Image source: Getty Images.
Source Fool.com
